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Background: Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease in which the platelet count falls
to <100 × 109/L. Corticosteroids are recommended as the first-line treatment, splenectomy is recommended as the
second-line treatment, and thrombopoietin receptor agonists (TPO-RAs) and rituximab are recommended as the
third-line treatments for ITP in Japanese ITP treatment guidelines. However, in Japan, rituximab is not eligible for
reimbursement for the treatment of ITP. The cost-effectiveness of ITP treatment has not been investigated in Japan.
Therefore, in this study, the cost-effectiveness of adding rituximab treatment to the existing treatments indicated
for ITP in Japan, namely splenectomy and the TPO-RA romiplostim, was investigated based on the scenario that
rituximab is eligible for reimbursement in Japan as a treatment for ITP.
Methods: The efficacy endpoint was set as the number of years with a platelet count ≥30 × 109/L. The analysis was
conducted from the healthcare payer’s perspective. If the first treatment is ineffective or relapse occurs, then the patient
is given the following treatment. The analyzed treatment order consisted of three patterns: splenectomy-romiplostim
(sequence 1), splenectomy-romiplostim-rituximab (sequence 2), and splenectomy-rituximab-romiplostim (sequence 3). A
Markov model was built for ITP, and the analysis period was set as 2 years. The discount rate was an annual rate of 2%.
Sensitivity analyses of the efficacy of splenectomy, romiplostim, and rituximab; treatment cost; and romiplostim dose
were performed.
Results: The expected costs per patient over a 2-year period for sequences 1, 2, and 3 were USD 40,980, USD 39,822,
and USD 33,551, respectively. The expected years with a platelet count ≥30 × 109/L for the three sequences were 1.75,
1.79, and 1.78 years, respectively. The sensitivity analyses illustrated that the results of the base case analysis were robust.
Conclusions: Adding rituximab to standard treatment for ITP (sequences 2–3) is less costly and marginally more
effective than standard therapy in adults. According to the study results, if rituximab is reimbursed for the treatment of
ITP in Japan, medical expenses are expected to decline.
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Idiopathic thrombocytopenic purpura (ITP) is an auto-
immune disease in which the platelet count falls to
<100 × 109/L. There are approximately 20,000 patients
with this disorder in Japan, and it is reported that
approximately 3,000 people develop this disorder every
year.
The pathology of the disorder involves destruction of
autoantibody-presenting platelets by the spleen and liver,
and insufficient hematopoiesis of megakaryocytes is also
observed because of the relative shortage of the mega-
karyocyte hematopoietic factor thrombopoietin. ITP is
classified based on the length of time from the diagnosis
as follows: newly diagnosed, <3 months; persistent,
between 3 and 12 months; and chronic, >12 months.
Ninety percent of patients with adult-onset ITP have
chronic disease, and the male-to-female ratio is 1:2.
Approximately 10% of all patients with ITP do not
respond to standard treatment, and cases in which the
platelet count falls to <30 × 109/L are considered intract-
able. The mortality rate of patients with ITP is 4.2-fold
higher than that of healthy individuals [1]. However,
opportunities to select immunosuppressive agents have
declined because of the current availability of rituximab
and thrombopoietin receptor agonists (TPO-RAs), and it
is possible that the risk of death, even if the platelet
count is <30 × 109/L, is no longer 4.2-fold higher than
that of healthy individuals.
The Japanese ITP treatment guidelines are as follows.
Patients with ITP who are infected with Helicobacter
pylori first receive H. pylori eradication therapy [2],
which recovers the platelet count to 100 × 109/L in
approximately half of all patients. However, when H.
pylori eradication therapy is ineffective or patients are
not infected with H. pylori, corticosteroid treatment is
the first-line treatment option, and this treatment is
highly effective. However, only 10%–20% of all patients
can discontinue corticosteroid administration, and most
patients require long-term corticosteroid treatment in
Japan. This long-term corticosteroid treatment is signi-
ficantly problematic clinically because it causes side
effects such as diabetes, hypertension, peptic ulcers, and
immunodeficiency.
When corticosteroids are ineffective or there are
problems with tolerability, a splenectomy is the second-
line treatment option. The efficacy rate of splenectomy
is reported to be approximately 60%, although relapses
are also reported [3]. The drawbacks of splenectomy are
risks such as perioperative complications experienced
by 10% of subjects, the mortality rate of 1% associated
with the laparotomic portion of the procedure, the mor-
tality rate of 0.2% associated with laparoscopic surgery,
and severe infection because of postoperative immuno-
deficiency [1,3].Patients for whom the splenectomy was ineffective or
who are not candidates for surgery can receive third-
line treatment with the anabolic steroid danazol, the
immunosuppressants azathioprine and cyclosporine, the
anticancer agents vincristine and cyclophosphamide,
the TPO-RAs romiplostim and eltrombopag, and the
anti-CD20 monoclonal antibody rituximab. Among the
third-line treatment options, only TPO-RAs are covered
by health insurance in Japan, and romiplostim and
eltrombopag were approved after 2011. TPO-RAs are
effective in approximately 60%–90% of intractable cases;
however, once treatment is discontinued, the platelet
count decreases to the pre-treatment level within 2 weeks
[4-6]. This demands long-term treatment, which places
financial pressure on the patient because of high drug
costs. It was recently reported that some patients do not
experience a relapse after TPO-RA discontinuation.
However, further investigation via a larger-scale, longer-
term observational study is required because these data
were obtained from a short-term observational study
involving a small number of subjects.
By contrast, another third-line treatment option, ritux-
imab, basically requires only four doses administered at
weekly intervals, and the patient can expect a radical
cure; thus, this drug is less expensive than TPO-RAs. In
a systematic review of the curative effect of rituximab
targeting approximately 300 patients with ITP, it was
reported that the platelet count exceeded 50 × 109/L in
62.5% of patients [7]. The median response duration is
limited; after 5 years, 20%–25% of patients have suffi-
cient platelet counts [7]. Rituximab is described as a
second-line treatment option for intractable ITP in the
American guidelines [5]. However, in Japan, there are
few records of the use of rituximab for treating ITP;
therefore, it is not indicated for ITP, and it is currently
used off-label [8]. ITP was specified as an intractable
disease in 1974 in Japan, and some patients are eligible
for public financial support from the national and pre-
fectural governments. However, drugs such as rituximab
that are not indicated for ITP are neither eligible for
public financial assistance nor are they covered by insur-
ance. The reality is that these drugs are used off-label to
save the lives of patients with intractable ITP. At this
juncture, clinical trials are currently underway under the
assumption that rituximab is eligible for reimbursement
in Japan as a treatment for ITP.
Recently, there has been increased interest in Japan in
the evaluation of medical economy, with investigations
into the introduction of the Health Technology Assess-
ment (HTA) by the Central Social Insurance Medical
Council. However, the cost-effectiveness of ITP treat-
ment has not been investigated in Japan. There are
reports overseas that investigated the cost-effectiveness
of TPO-RA with standard ITP treatments, including
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gated the cost-effectiveness of splenectomy followed by
romiplostim (sequence 1) and splenectomy-romiplostim
plus rituximab (sequences 2–3).
In this study, based on the scenario that rituximab is
eligible for reimbursement in Japan as a treatment for ITP,
we investigated the cost-effectiveness of adding rituximab
to splenectomy and the TPO-RA romiplostim.
Methods
The aim of this study was to clarify the cost-effectiveness of
adding rituximab to conventional treatments for ITP in
adults, namely splenectomy and romiplostim. A Markov
model was built for ITP, and the analysis period was set at
2 years. The efficacy endpoint was the number of years with
a platelet count ≥30 × 109/L: the level required to prevent
life-threatening blood loss. The costs were set as the direct
medical costs. The analysis was conducted from the health-
care payer’s perspective. All costs are shown in US dollars.
Treatment option
A typical adult patient with intractable ITP for whom
the first treatment option of corticosteroids is ineffective
was set as a target Japanese woman of 50 years of age,
60 kg in weight, and 160 cm in height.
In accordance with the Japanese ITP treatment guide-
lines, a patient with intractable ITP who is non-responsive
to corticosteroids undergoes splenectomy. If the splenec-
tomy is ineffective or relapse occurs, then the patient is
switched to romiplostim or rituximab treatment. Further-
more, if romiplostim is ineffective, then the patient is
switched to rituximab, and if rituximab is ineffective, the
patient is then switched to romiplostim. If splenectomy,
romiplostim, and rituximab are all ineffective or relapse
occurs, then the patient is switched to maintenance
therapy using corticosteroids. Because this study tar-
geted patients with intractable ITP, the analysis started
with the second-line treatment option of splenectomy.
Therefore, the analyzed treatment order consisted of
three patterns as follows: splenectomy-romiplostim
(sequence 1), splenectomy-romiplostim-rituximab (se-
quence 2), and splenectomy-rituximab-romiplostim






Figure 1 Analyzed treatment order for idiopathic thrombocytopenicPrior to undergoing splenectomy, the patient is admin-
istered five doses of 0.4 g/kg IVIG as an outpatient ther-
apy to adequately increase the platelet count, and the
splenectomy is performed during a 7-day hospitalization.
At present, two TPO-RAs are indicated for treating
ITP in Japan, and for this study, we conducted a simula-
tion using one of those products, romiplostim. Romi-
plostim is an injectable treatment that is administered at
1–10 μg/kg body weight per week. The dose will be
titrated individually, and in some patients, it is possible
to use a much lower dose than the licensed dose. The
dose in this study was 4 μg/kg based on the results of
long-term continuation tests in Japanese patients; there-
fore, a dose of 240 μg was calculated for a 60-kg patient.
One vial of romiplostim contains 250 μg of the drug.
Therefore, one vial is used per dose, assuming that the
remainder would be discarded [12].
A single dose of rituximab was set at 375 mg/m2, and
it was assumed that a total of four doses would be
administered at weekly intervals. The initial dose of
rituximab requires the patient to stay in the hospital
overnight, whereas the remaining three doses are admin-
istered in the outpatient setting.
Assuming that sepsis would occur during the splenec-
tomy and rituximab treatment period as well as after
treatment, any affected patient would be hospitalized for
treatment [7,13]. Concerning the romiplostim treatment
period, pulmonary embolism was assumed as the ad-
verse event, and any affected patient would be hospital-
ized for treatment [14].
Emergency treatment for exacerbation of ITP symptoms
such as a rapid decline in the platelet count and hemorrhage
involved hospitalization and IVIG administration.
If the platelet count does not reach or exceed 30 × 109/L
after splenectomy, romiplostim, and rituximab treatment,
corticosteroids (20 mg/day) was administered as a main-
tenance therapy.
Model design
We created a model of the typical clinical course of ITP
using a Markov model based on the advice of ITP
specialists (Figure 2). One cycle consisted of 4 weeks





Figure 2 Structure of the model. AE: adverse event, PL: platelet, SP: splenectomy, RO: romiplostim, RI: rituximab. The model is composed of six
states. Each cycle was a 28-day period. The cycle starts from the idiopathic thrombocytopenic purpura (ITP) treatment state (PL <30 × 109/L) and
moves to the next state after 28 days. However, if PL remains <30 × 109/L after the treatment, the cycle remains at the ITP treatment state. The
broken line shows the flow of patients treated with splenectomy and rituximab, i.e., patients who received treatments other than romiplostim.
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to the American guidelines for ITP [5]. The transfer rates
to each of the disease states were summarized based on
academic reports and specialists’ opinions. “Effective” was
defined as a platelet count ≥30 × 109/L after treatment.
“Relapse” was defined as a platelet count ≥30 × 109/L after
treatment that subsequently declined to 30 × 109/L.
The model was created based on the following
assumptions. If splenectomy and rituximab treatment are
effective, then there is no subsequent treatment. If the
treatment is ineffective or the patient relapses, the patient
is then switched to the following treatment. Assuming that
the adverse event during the perioperative period of splen-
ectomy and rituximab administration or after these treat-
ments was sepsis, the patient would receive the treatment
for sepsis for 4 weeks, after which the original treatment
would be resumed. If romiplostim treatment is effective,
then the patient would continue this treatment. If the
treatment is ineffective, the patient would then be
switched to the following treatment. If pulmonary em-
bolism occurred during romiplostim treatment, the pa-
tient would discontinue treatment with romiplostim
and receive 4 weeks of treatment for the pulmonary em-
bolism. If emergency treatment is required because of
exacerbation of ITP symptoms in any of the treatment
groups, the patient would be hospitalized for 4 weeks
and administered IVIG, after which the original treat-
ment would be resumed. If no effect is observed after
treatment with splenectomy, romiplostim, and rituxi-
mab or if relapse occurs, the patient would then receive
maintenance therapy with corticosteroids. However,
because this study targeted intractable ITP that was
non-responsive to corticosteroids, the platelet countwould remain at <30 × 109/L even after corticosteroid
administration. The adverse event assumed to occur
during corticosteroid maintenance therapy was diabetes,
and if diabetes occurred, corticosteroid maintenance ther-
apy would be continued while also administering diabetes
treatment.
Model inputs
The efficacy rates, relapse rates, and incidence of adverse
events obtained from the literature are presented in
Table 1. These rates were used as the transfer rates be-
tween the states.
The annual mortality rate was calculated by multiply-
ing the mortality rate of the target patients (Japanese
women aged 50 years) by the risk of mortality based on
reports indicating that the mortality risk of patients with
ITP and a platelet count <30 × 109/L is 4.2-fold higher
than that of healthy subjects, compared to 1.8-fold
higher than that of patients with a platelet count ≥30 ×
109/L [1]. The mortality rate of 0.02% associated with
surgery was added when splenectomy was conducted.
The costs used for the analysis are shown in Table 2.
The costs were set as the direct medical costs from the
healthcare payer’s perspective. All costs are shown in US
dollars. The National Health Insurance drug prices re-
vised on April 1, 2012 were used to determine the cost
of each drug. The items and number of standard tests
and treatments were determined based on the ITP
Treatment Guidelines and the opinions of ITP special-
ists. The cost for one cycle (28 days) was summed based
on the hospital and treatment fee schedule. Currency
conversions were calculated using the exchange rate as
of November 2013 (1 USD = JPY100).
Table 1 Probability parameters
Events Splenectomy Romiplostim Rituximab Corticosteroids
Efficacy rates 76.1% [15] 84.1% [14] 71.6% [16,17] ―
Relapse rates 0.45% [3] 0%* 0.88% [18] ―
Adverse event rates 0.44% [13] 0.58% [14] 0.24% [7] 11% [19]
Emergency treatment rates (PL < 30 × 109/L) 14.4% [20] 14.4% [20] 14.4% [20] 26.8% [20]
Emergency treatment rates (PL≥ 30 × 109/L) 0.4% [20] 0.4% [20] 0.4% [20] ―
Mortality rate (PL < 30 × 109/L) GR (%) × 4.2 + 0.02%†[1,3,21] GR (%) × 4.2 [1,21] GR (%) × 4.2 [1,21] GR (%) × 4.2 [1,21]
Mortality rate (PL≥ 30 × 109/L) GR (%) × 1.8 [1,21] GR (%) × 1.8 [1,21] GR (%) × 1.8 [1,21] GR (%) × 1.8 [1,21]
PL: platelet, GR: General mortality rate. References are given in brackets.
*If romiplostim treatment is effective, then relapse would not occur.
†A mortality rate of 0.02% was added when splenectomy was conducted.
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the guidelines for the economic evaluation of healthcare
technologies in Japan [22].Cost-effectiveness
The expected costs required for a patient to receive
treatment for 2 years for sequences 1–3 were calculated
based on the transfer rate to each of the disease states
obtained from the literature and the cost of each compo-
nent (Table 2). The efficacy endpoint was set as the
number of years with a platelet count ≥30 × 109/L. The
cost-effectiveness ratio was set as 2-year expected cost/
years with a platelet count ≥30 × 109/L. The cost re-
quired to maintain the platelet count at ≥30 × 109/L for
1 year. We compared the cost-effectiveness ratio for se-
quences 1, 2, and 3.Sensitivity analyses
Unless the cost-effectiveness ratio of sequence 2 is larger
than that of sequence 1, sequence 2 is cost-effective
compared to that of sequence 1. The relationship is con-
sidered the same between sequences 1 and 3; therefore,
a sensitivity analysis was conducted focusing on the
differences between these cost-effectiveness ratios.Table 2 Cost parameters
Item Cost (USD/28 days)





Treatment for AE Sepsis 4,329
Pulmonary embolus 4,101
Diabetes 243
Emergency treatment IVIG 15,533
AE: adverse event.The efficacy of splenectomy, romiplostim, and rituximab
varied by 50% below the base case analysis in sensitivity
analyses. Concerning the costs, the costs of splenectomy,
rituximab, and emergency treatment varied by 50% above
and below the base case analysis in sensitivity analyses.
Furthermore, in the sensitivity analyses, the romiplostim
dose was set as two vials per dose instead of one vial as set
in the base case analysis because even slight changes in
body weight would lead to changes in the number of vials
if the remainder of the drug was assumed to be discarded.
Results
Cost-effectiveness
The expected costs per patient over a 2-year period are
shown in Table 3. The expected costs per patient over a
2-year period for sequences 1, 2, and 3 were USD
40,980, USD 39,822, and USD 33,551, respectively.
The cost-effectiveness ratio or 2-year expected cost/
years with a platelet count ≥30 × 109/L, was USD 23,438
for sequence 1, USD 22,280 for sequence 2, and USD
18,826 for sequence 3 (Table 3, Figure 3).
The results of the base case analysis illustrated that
the addition of rituximab (sequences 2–3) was cost-
effective compared to that of splenectomy-romiplostim
(sequence 1).
Sensitivity analyses
Table 4 presents the differences in cost-effectiveness ra-
tios between sequences 1 and 2 and between sequences
1 and 3. The sensitivity analysis was conducted using the
differences in these cost-effectiveness ratios. The efficacy
of splenectomy had the most significant effect in the
sensitivity analyses. When the efficacy of splenectomy
varied by 50% below the base case analysis, the differ-
ences between the cost-effectiveness ratios of sequences
1 and 2 and between sequences 1 and 3 increased from
USD 1,158 to USD 3,707 and from USD 4,612 to USD
12,503, respectively (Figure 4). When the rituximab effi-
cacy varied by 50% below the base case analysis, the differ-
ences between the cost-effectiveness ratios of sequences 1
Table 3 Result of base case analysis
Treatment order 2-year expected
cost (USD)
Expected period of the







Sequence 1 40,980 1.75 87.02 224.47 140.96 23,438
Sequence 2 39,822 1.79 85.44 114.78 110.66 22,280
Sequence 3 33,551 1.78 85.65 106 128.83 18,826
PL: platelet, AE: adverse event.
*The period was calculated as NS · P/NT, where NS, P, and NT denote the average number of people in the PL ≥ 30 × 10
9/L states in the simulated population, the
duration of simulation (2 years), and the total number of people simulated, respectively (10,000).
†The number of patients among 10,000 people.
‡Assuming sepsis would occur during the splenectomy and rituximab treatment period as well as after treatment. Pulmonary embolism was assumed to be the
adverse event for romiplostim treatment.
§Using these AE incidence rates as the rates of transition among the states of the Markov model to a state of “treatment for AE,” we calculated the number of
people who developed adverse events in 2 years in a 10,000-person population.
|| Two-year expected cost (USD)/period of PL ≥ 30 × 109/L (years).
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USD 1,158 to USD 406 and from USD 4,612 to USD
1,079, respectively, but the difference did not fall below 0
(Figure 4).
The costs of the treatments did not have great influ-
ence on the differences between the cost-effectiveness
ratios.
When the romiplostim dose was set as two vials per
dose, the difference between the cost-effectiveness ratios
of sequences 1 and 3 increased from USD 4,612 to USD
10,603 (Figure 5).
The sensitivity analyses revealed that the results of the
base case analysis were robust.
Discussion
This study created an independent model in which the
standard platelet count used for the endpoint was set at
30 × 109/L, with states including hemorrhage and adverse
events. Using this model, we examined the cost-
effectiveness of ITP treatment in which rituximab, for
which clinical trials are underway to support approval
for this indication in Japan, is added to splenectomy
and the TPO-RA romiplostim, which are currentlyFigure 3 Relationship between 2-year expected cost and period
of the PL ≥ 30 × 109/L. PL: platelet, SP: splenectomy, RO:
romiplostim, RI: rituximab.indicated for the treatment of ITP in Japan. The treat-
ment costs associated with ITP treatment have been
reported mainly for IVIG and splenectomy. However,
there are few reports that investigated the cost-effectiveness
of ITP treatment with a Markov model. In the reports
that investigated the cost-effectiveness of ITP treat-
ment, the cost-effectiveness of IVIG was compared with
that of corticosteroids [23], or the cost-effectiveness of
standard treatment including rituximab was compared
with that of a combination of standard treatment and
romiplostim [9,11].
The following points can be highlighted as unique to our
analyses. First, this study examined the cost-effectiveness
of only 3 treatments: splenectomy, romiplostim, and
rituximab. In the Japanese guidelines, danazol, azathio-
prine, and cyclophosphamide are recommended as
third-line treatment options, in addition to TPO-RAs
and rituximab. However, we considered that the American
guidelines for ITP [5] recommend only splenectomy,
TPO-RAs and rituximab as second-line treatment options,
and TPO-RAs represent the only third-line treatment
option covered by medical insurance in the Japanese
guidelines. In addition, clinical trials of rituximab are
underway to support the approval of the drug for treating
ITP in Japan. Second, in previous studies, effectiveness
was defined as achieving a platelet count ≥50 × 109/L,
whereas in this study, the evaluation endpoint was set as
the number of years with a platelet count ≥30 × 109/L.
Because rituximab is recommended in the American
guidelines for ITP [5] when the platelet count falls below
30 × 109/L, which also increases the risk of death or
hemorrhage, we considered that the endpoint should be
set as a platelet count of 30 × 109/L. Third, several previ-
ous studies only considered hemorrhage as an adverse
event, whereas we evaluated the adverse events that are
expected to have a significant effect on the cost-
effectiveness in each treatment based on specialists’ opin-
ions and the literature. Fourth, in the application data of
romiplostim for NICE, the study was conducted on the
premise that the efficacy of romiplostim differs before and
Table 4 Cost-effectiveness ratio
Treatment order 2-year expected
cost (USD)
Expected period of the





Sequence 1 40,980 1.75 23,438 ー
Sequence 2 39,822 1.79 22,280 1,158†
Sequence 3 33,551 1.78 18,826 4,612‡
PL: platelet.
* Two-year expected cost (USD)/period of PL ≥30 × 109/L (years).
†Differences in the cost-effectiveness ratios between sequences 1 and 2.
‡Differences in the cost-effectiveness ratios between sequences 1 and 3.
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difference in the efficacy of romiplostim before and after
splenectomy is not clear, and this difference may arise
from the different durations of disease prior to the start of
romiplostim treatment; thus, in this study, the analysis
was conducted assuming that the efficacy of romiplostim
was the same before and after splenectomy.
This study demonstrated that adding rituximab to
splenectomy-romiplostim (sequence 1) reduces the
treatment cost over a 2-year period, extends the period
with a platelet count ≥30 × 109/L, reduces the number of
deaths, and reduces the number of patients manifesting
adverse events as well as those requiring emergency
treatment (Table 3). The reductions in the numbers
of deaths, patients manifesting adverse events, and
patients requiring emergency treatment is probably
because the shortened length of time for the platelet
count falls to <30 × 109/L by adding rituximab com-
pared to those of splenectomy and romiplostim alone.
The reduction in cost is largely related to the fact that
although some patients relapsed, patients who achieved
a complete cure and required no further treatment were
by no means rare.Figure 4 Results of sensitivity analyses on efficacy rates. The efficacy o
base case analysis. Broken lines denote the results of the difference in the
cost-effectiveness ratios between sequences 1 and 2. (b) Difference in costThe application data for eltrombopag for NICE indi-
cated that treatment in the order of rituximab→ eltrom-
bopag→ romiplostim→ IVIG is cost-effective [10].
Mowatt et al. reported that the administration of rituxi-
mab prior to standard treatment is cost-effective [9].
This information is consistent with the results of this
study, in which the cost-effectiveness ratio of splenectomy-
rituximab-romiplostim (sequence 3) was lower than that
of splenectomy- romiplostim-rituximab (sequence 2).
However, the numbers of deaths and adverse events for
sequence 2 were lower than those for sequence 3.
Therefore, further long-term investigation using quality-
adjusted life years (QALY) is needed to determine whether
sequence 2 or 3 is more cost-effective.
The results of the sensitivity analysis illustrated that
the efficacy of splenectomy had the most significant
effect on the difference in the cost-effectiveness ratio
between sequences 1 and 2. This is probably because the
reduction in the efficacy of splenectomy increases the
number of subjects who move to maintenance therapy,
which results in an increased number of patients who
require emergency treatment in sequence 1. The efficacy
of splenectomy and the romiplostim dose significantlyf splenectomy, romiplostim, and rituximab varied by 50% below the
cost-effectiveness ratio in the base case analysis. (a) Difference in the
-effectiveness ratios between sequences 1 and 3.
Figure 5 Sensitivity analysis of cost and the romiplostim dose. The treatment costs varied by 50% above and below the base case analysis,
and the romiplostim dose varied from one to two vials. Broken lines denote the results of the difference in the cost-effectiveness ratios in the
base case analysis. (a) Difference in the cost-effectiveness ratios between sequences 1 and 2. (b) Difference in the cost-effectiveness ratios be-
tween sequences 1 and 3.
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tween sequences 1 and 3. Regarding the romiplostim
dose, it is considered that more subjects were adminis-
tered romiplostim in sequence 1 than in sequence 3,
which had a marked effect on the cost because of the
increased romiplostim dose and resulted in a larger
difference in the cost-effectiveness ratios between the
sequences. It is possible that the mortality rate, even if
the platelet count is <30 × 109/L, is no longer 4.2-fold
higher than that of the healthy population because the
referred mortality rate was determined prior to the avail-
ability of rituximab and romiplostim. Therefore, assum-
ing that the mortality rate was 2.1-fold higher than that
in healthy individuals, which is half of the mortality rate
of the base analysis, we conducted the sensitivity ana-
lyses to assess the impact of the mortality rate. The
mortality rate did not have great influence on the base
case analysis.
The first limitation of this study was that we did not
use utility. This is because there are no reports on utility
in cases of complications with ITP or relapse, although
one study used utility with the presence or absence of
hemorrhage and another report mapped SF36 to SF-6D
[9,10]. Therefore, we did not determine whether sequence
2 or 3 is more cost-effective in this study. We would like
to accumulate data on utility for patients with ITP who
developed complications. Second, the analysis period was
2 years, which did not reflect long-term drug use. Similar
to this study, cost-effectiveness according to the order of
treatment was analyzed in the application data to NICE
for eltrombopag, and the analysis period in this study was
2 years [10]. In this study, we used a 2-year analysis periodin reference to this previous study. It should be noted that
although the analysis period in previous cost-effectiveness
analysis of romiplostim was a lifetime, we did not use this
because safety concerns such as the development of bone
marrow fibrosis remains regarding the long-term use of
TPO-RAs. Third, the efficacy rates of rituximab and splen-
ectomy and the rate of relapse in this study were cited
from foreign reports. However, clinical trials of rituximab
are underway in Japan, and we plan to use domestic data
for investigations as soon as the results become available.
Fourth, eltrombopag is another TPO-RA approved in
Japan in addition to romiplostim, but we selected romi-
plostim in this study because eltrombopag was not recom-
mended by NICE in the UK once. The efficacy, cost, and
administration methods of romiplostim are different from
those of eltrombopag. Therefore, we conducted sensitivity
analyses of the efficacy and cost of romiplostim. However,
the results of the base case analysis were robust. Fifth, we
assumed that when rituximab or splenectomy was effect-
ive, no further treatment would be undertaken. However,
ITP therapeutic agents including corticosteroids are con-
tinuously administered in some cases. We also assumed
that romiplostim was administered as a monotherapy, but
in fact, other drugs such as corticosteroids are sometimes
used in combination. In this study, however, we assumed
no treatment considering the state in which the concomi-
tant use of corticosteroids is avoided as much as possible
because of its adverse events. Sixth, the actual mainten-
ance therapy depends on a variety of factors. However, we
assumed that steroid therapy would be administered as
the maintenance therapy when none of the treatments
such as splenectomy, romiplostim, and rituximab was
Kikuchi et al. BMC Health Services Research  (2015) 15:2 Page 9 of 9effective or relapse occurred. We selected the treatment
based on the relevant guidelines and specialists’ opinions.
Conclusions
The expected costs per patient over a 2-year period for
sequences 2 and 3 were lower than those for sequence 1.
The expected number of years with a platelet count
≥30 × 109/L was greater for sequences 2 and 3 than for
sequence 1.
Based on these results, the addition of rituximab
(sequences 2–3) results in lower treatment costs and
greater efficacy compared to that of standard treatment
for ITP in adults. According to the study results, if rituxi-
mab is reimbursed for the treatment ITP in Japan, medical
expenses will be reduced.
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